Home > Insider Trading > Filing (0000899140-24-001036)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1638287	Neurobo Pharmaceuticals Inc.	NRBO	Pharmaceutical Preparations (2834)	472389984

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1799260	Dong-A St Co., Ltd	64, Cheonho-Daero Dongdaemun-Gu Seoul M5 02587		No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2024-09-12	407	$3.75	5,347,792	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Warrants to Purchase Common Stock	Acquisiton	2024-09-18	2,544,530	$0.00	2,544,530	$3.93
Common Stock	Warrants to Purchase Common Stock	Acquisiton	2024-09-18	3,816,795	$0.00	3,816,795	$3.93

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
2,544,530	2024-09-18	2025-09-18	No	4	P	Direct
3,816,795	2024-09-18	2029-09-18	No	4	P	Direct

Footnotes

Reporting Person's sale of 407 shares of Common Stock at a price per share of $3.75 occurred on September 12, 2024.
On June 13, 2024, the Issuer issued (i) Series A Warrants to purchase up to an aggregate of 2,544,530 shares of the Issuer's common stock (the "Series A Warrant Shares") and (ii) 3,816,795 Series B Warrants to purchase up to an aggregate of 3,816,795 shares of the Issuer's common stock (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants"), to the reporting person pursuant to a securities purchase agreement dated the same date (the "Purchase Agreement"), in connection with a private placement of securities by the Issuer to certain investors. The issuance of the Warrants under the Purchase Agreement was subject to stockholder approval under applicable NASDAQ rules, which was obtained at a special meeting of the Issuer's stockholders held on September 18, 2024.
These warrants expire on the earlier of (i) the twelve months anniversary of September 18, 2024, and (ii) the 60th day following the date on which the Issuer publicly announce the receiving of positive Phase 1 MAD data readout for DA-1726.
These warrants expire on the earlier of (i) the five years anniversary of September 18, 2024 and (ii) the six months anniversary following the date on which the Issuer publicly announce the receiving of positive Phase 1, Part 3 data readout for DA-1726.